LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the fourth quarter and year ended December 31, 2015, along with a general business update. Aerie Highlights With the Company’s successful Rocket 2 topline safety and efficacy readout
ATHENS, Greece — In welcoming the audience of the 20th European Society of Cataract and Refractive Surgeons winter meeting, ESCRS president David Spalton, MD, said he was honored and delighted to do so in the city that gave birth to modern medicine 2,500 years ago.“It is amazing to look out of my bedroom’s window, see the Acropolis and think that there is where everything started. In the golden age of Pericles, Hippocrates established the basic principles and ethics of modern medicine. His ‘do no harm’ is still underlying our medical (Read more...)
NS2, an aldehyde-binding small molecule, reduced ocular itching and tearing in subjects with allergic conjunctivitis, according to phase 2a study results announced in a press release from Aldeyra Therapeutics.The study included 100 subjects with a 2-ye…
ATLANTA – In a special session here at SECO, John Berdahl, MD, theorized that glaucoma results when the difference between the cerebrospinal fluid and intraocular pressures is too great.Berdahl said he evaluated 50,000 patients who had lumbar puncture over the course of 20 years and found that intracranial pressure (ICP), or cerebrospinal fluid (CSF) pressure, was lower in people who had glaucoma and higher in people with ocular hypertension.
The U.S. Preventive Services Task Force (USPSTF) has concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity…